Oruka Therapeutics psoriasis drug clears skin in 64% of patients

Oruka Therapeutics announced positive Phase 2 trial results for its investigational drug ORKA-001, showing 64% of patients with moderate-to-severe psoriasis achieved clear or almost clear skin at 16 weeks. The drug also met all secondary endpoints, including improvements in itch and quality of life. Updated data suggest the potential for once-yearly dosing, which could differentiate ORKA-001 from existing treatments that require more frequent administration. The trial enrolled 200 patients across multiple sites. Oruka plans to advance the drug into Phase 3 trials. Psoriasis affects approximately 125 million people worldwide, and current biologic therapies often require injections every few weeks or months. The company is also developing a second candidate, ORKA-002, for other inflammatory conditions.